Acalabrutinib Plus Venetoclax: FDA Approves Dual BTK-Bcl-2 Targeting for CLL
The FDA’s Q1 2026 approval of acalabrutinib combined with venetoclax for CLL marks a new era in dual-target therapy, combining BTK inhibition with Bcl-2 antagonism.
Category Archives: Signaling Pathways
STAT3 Inhibitors: Targeting the Transcription Factor at the Heart of Cancer Signaling
Discover STAT3 inhibitors including Stattic and napabucasin, and how targeting this central transcription factor in cancer signaling offers novel therapeutic opportunities in solid and hematologic malignancies.
TYK2 Inhibitors: The Next Frontier in Selective JAK-STAT Pathway Targeting
Explore TYK2 inhibitors like deucravacitinib and discover how allosteric pseudokinase domain targeting offers selective advantages over pan-JAK inhibitors in treating psoriasis, lupus, and inflammatory diseases.
JAK Inhibitors: Selective vs Pan-JAK Compounds for Autoimmune and Cancer Research
Explore pan-JAK inhibitors (tofacitinib), selective JAK1/2 inhibitors (ruxolitinib), and JAK1-preferential compounds (filgotinib) for autoimmunity and cancer research.
AKT Inhibitors: Allosteric vs ATP-Competitive Approaches to AKT Targeting
Compare allosteric (MK-2206) and ATP-competitive (capivasertib, AZD5363) AKT inhibitors to understand their mechanisms, isoforms, and optimal research applications.
mTOR Inhibitors: Rapalogs vs ATP-Competitive vs Dual PI3K/mTOR Compounds
Compare rapalogs, ATP-competitive mTOR inhibitors, and dual PI3K/mTOR compounds to choose the right inhibitor class for your research.
PI3K Inhibitors: From Pan-PI3K to Isoform-Selective – Choosing Research Compounds
Navigate PI3K inhibitor development from pan-PI3K agents to isoform-selective compounds like alpelisib. Learn how isoform-specific biology drives targeted therapeutic approaches.
